A pan-cancer analysis of the frequency of DNA alterations across cell cycle activity levels

Abstract
Pan-cancer genomic analyses based on the magnitude of pathway activity are currently lacking. Focusing on the cell cycle, we examined the DNA mutations and chromosome arm-level aneuploidy within tumours with low, intermediate and high cell-cycle activity in 9515 pan-cancer patients with 32 different tumour types. Boxplots showed that cell-cycle activity varied broadly across and within all cancers. TP53 and PIK3CA mutations were common in all cell cycle score (CCS) tertiles but with increasing frequency as cell-cycle activity levels increased (P < 0.001). Mutations in BRAF and gains in 16p were less frequent in CCS High tumours (P < 0.001). In Kaplan–Meier analysis, patients whose tumours were CCS Low had a longer Progression Free Interval (PFI) relative to Intermediate or High (P < 0.001) and this significance remained in multivariable analysis (CCS Intermediate: HR = 1.37; 95% CI 1.17–1.60, CCS High: 1.54; 1.29–1.84, CCS Low = Ref). These results demonstrate that whilst similar DNA alterations can be found at all cell-cycle activity levels, some notable exceptions exist. Moreover, independent prognostic information can be derived on a pan-cancer level from a simple measure of cell-cycle activity.
Funding Information
  • Iris, Stig och Gerry Castenbäcks Stiftelse for cancer research;
  • Susan G. Komen (SAC-160074)
  • Breast Cancer Research Foundation
  • NCI Breast SPORE program
  • Stiftelsen Konung Gustaf V:s Jubileumsfond
  • Cancerfonden
  • Vetenskapsrådet
  • BRECT; Cancer Society in Stockholm Personalised Cancer Medicine (PCM); Swedish Breast Cancer Association;